Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 63Specimen Handling 58pembrolizumab 40enzalutamide 38Nivolumab 32Gemcitabine 30Docetaxel 28Biopsy 25Prednisone 23Abiraterone Acetate 21apalutamide 20Androgen Antagonists 19Radiosurgery 18Cisplatin 18darolutamide 16cabozantinib 16abiraterone 16Radiotherapy 16enfortumab vedotin 15Radiation 14Ipilimumab 13belzutifan 12Pluvicto 12Mitomycin 12olaparib 11erdafitinib 11durvalumab 11atezolizumab 11X-Rays 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tiragolumab × Genitourinary × 30 days × Clear all
NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Active not recruiting
199 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡